FDA Approves ANDA for Carfilzomib by MSN
The FDA has approved the ANDA209526 application for Carfilzomib submitted by MSN.
Therapeutic Area
Therapeutic area intelligence for Proteasome Inhibitor with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No related entities indexed yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.